Financial Performance - GMV reached RMB 727 billion, showing seven consecutive quarters of year-over-year growth[6] - Revenue reached RMB 666 billion, also marking seven consecutive quarters of year-over-year growth[6] - Non-GAAP net profit was RMB 1013 million, achieving twelve consecutive quarters of Non-GAAP profitability with a margin of 15%[6] - GAAP net profit was RMB 829 million, demonstrating seven consecutive quarters of GAAP profitability with a margin of 12%[6] - Gross profit was RMB 19226 million with a gross margin of 289%[19] Operational Highlights - Good product SKUs accounted for 372% of the total in September, a +231 percentage point increase compared to January[7] - GMV from good products reached 447% of total GMV in September[7] - Core market GMV growth for Shanghai, Jiangsu, and Zhejiang was +14% year-over-year[7] - The number of monthly transacting users increased by +41% year-over-year[8] - Average monthly order per user was 46 orders, a +49% year-over-year increase[8] Cash Flow - The company had a RMB 1444 million operating cash inflow[25] - Self-owned fund balance was RMB 303 billion, showing a net increase for the ninth consecutive quarter[25] Strategy - The company is focusing on a high-volume, top-selling product strategy[9] - Expansion into smaller and medium-sized cities in the Jiangsu, Zhejiang, and Shanghai regions is underway, with 17 newly opened stations in Q3[10]

Financial Performance & Growth - Artivion achieved approximately $400 million in revenue and around $70 million in EBITDA for FY24[5] - The company is driving sustained double-digit revenue growth and expects 2x+ EBITDA growth[14] - Full year 2025 revenue guidance is between $439 million and $445 million, representing a year-over-year constant currency growth of 13-14%[73] - Full year 2025 adjusted EBITDA is expected to be between $88 million and $91 million, a year-over-year growth of 24-28%[76] - Net debt leverage is expected to decrease to less than 20x by year-end 2025, with net debt at 18x as of September 30, 2025[69] Business Segments & Market Opportunities - Preservation Services (CryoValve® SG) generated $98 million in revenue in 2024, holding the 1 market position with a 65% share in a $150 million global TAM[17] - Surgical Sealant (BioGlue) had $74 million in revenue in 2024, holding the 2 market position with a 28% share in a $260 million global TAM[17] - On-X aortic valve is uniquely positioned for younger AVR patients, creating a new $100 million U S market opportunity[24] - The company is focused on more complex, less competitive stent graft segments, with a 16% 3-year CAGR[38] - AMDS addresses a $150 million addressable market opportunity and is expected to receive PMA approval by mid-2026[41,46] Clinical Data & Product Performance - On-X aortic heart valve post-approval study (PAS) shows a 66% reduction in major events and an 87% reduction in major bleeding compared to the PROACT IDE study[20] - TRIOMPHE US IDE Trial for Endospan NEXUS® demonstrates a 63% reduction in major adverse event (MAE) rate compared to the reference performance goal[53] - AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control, with 269% MAEs in PERSEVERE vs 580% in the Hemiarch Reference Cohort[47]

Financial Performance & Guidance - Enlight achieved a 46% increase in quarterly revenues and income in 3Q25[10,15] - Adjusted EBITDA grew by 23% in 3Q25 compared to 3Q24[10,15] - The company is raising its 2025 revenue and income guidance to a range of $555-565 million, a 6% increase from the previous forecast[10,16,17] - Adjusted EBITDA guidance for 2025 is raised to $405-415 million, a 4.5% increase[10,16,17] - The company is aiming for an annual revenue and income run rate of approximately $1.5 billion by the end of 2027 and $2 billion by the end of 2028[10] Strategic Expansion & Portfolio Growth - Enlight is expanding its battery storage business with entry into the German and Polish markets[10] - The company acquired 50% of the Bertikow project and 100% of the Edison project to enter the German and Polish energy storage markets[25] - The Bertikow and Edison projects are expected to have a stand-alone storage capacity of 1.1 GWh with an expected first full year EBITDA of $45-49 million and $54-58 million respectively[26] - Enlight's total portfolio has reached 37 FGW (Factored GW), combining generation and storage capacity[44] - The mature portfolio, consisting of operational, under construction, and pre-construction projects, is expected to generate $1.6 billion in revenues and income[48] Capital & Financing - The company raised $4.8 billion in the past 12 months[33] - This includes approximately $1 billion in corporate finance and asset sales, $0.5 billion in tax equity partnerships, and $3.3 billion in project finance for projects in the US & Europe[34] - A $1.4 billion financial close was achieved for the Snowflake A project in Arizona, USA, with a capacity of 600 MW and 1900 MWh[37,38]

Company Overview - TME's online music paying users reached 125.7 million in 3Q25, with a paying ratio of 22.8%[8] - The platform boasts over 260 million music and audio tracks[12] - TME's last twelve months (LTM) total revenues as of 3Q25 were RMB 31.7 billion, with an adjusted net margin of 30.7%[12] - The company holds a strong cash position with RMB 36.08 billion in cash, cash equivalents, term deposits, and short-term investments[13] - Online music MAUs reached 551 million, with a monthly ARPPU of RMB 11.9, representing a YoY growth of 10.2%[13] Financial Highlights - Revenue from online music services in 3Q25 reached RMB 6.97 billion, a 27.2% YoY increase[36] - Revenue from music subscriptions in 3Q25 was RMB 4.50 billion, a 17.2% YoY increase[36] - Other online music services generated RMB 2.47 billion in revenue, a 50.6% YoY increase[36] - The online music monthly ARPPU in 3Q25 was RMB 11.9, a 10.2% YoY increase[37] - Non-IFRS net profit for 3Q25 was RMB 2.48 billion, a 27.7% YoY increase[37]

Financial Performance - Total sales reached $1.9 billion, a 6% year-over-year increase, with specialties-driven sales up by 3%[5] - Adjusted EBITDA increased by 4% year-over-year to $398 million[5] - Specialties-driven sales amounted to $1.5 billion, with an EBITDA of $251 million[5] Segment Performance - **Industrial Products:** Sales were $295 million, and EBITDA was $67 million, with a 23% EBITDA margin[8] - **Potash:** Sales increased to $453 million, and EBITDA reached $169 million, with a 37% EBITDA margin; average potash CIF price was $353 per ton[13, 16] - **Phosphate Solutions:** Sales were $605 million, and EBITDA was $134 million, with a 22% EBITDA margin; Phosphate Specialties sales were $348 million with $51 million EBITDA, while Phosphate Commodities sales were $257 million with $83 million EBITDA[19, 21] - **Growing Solutions:** Sales were $561 million, and EBITDA was $50 million, with a 9% EBITDA margin[23] Financial Position - Available cash resources totaled $1.5 billion[40] - Net debt to adjusted EBITDA ratio was 1.4x[40] - Quarterly dividend was $62 million, resulting in an annual yield of 2.8%[40] Guidance - The company maintains its full-year 2025 guidance for specialties-driven EBITDA between $0.95 billion and $1.15 billion[45] - Potash sales volumes are expected to be between 4.3 million metric tons and 4.5 million metric tons[45]

Financial Performance & Forecast - ORIX revised its FY26.3 net income forecast upward to 440 Billion JPY, a 15.8% increase from the previous forecast of 380 Billion JPY[6, 14] - The company increased its share buyback program to 150 Billion JPY, a 50% increase from the initial 100 Billion JPY program[6, 10] - H1 net income reached 271.1 Billion JPY, achieving 71% of the original full-year target and 62% of the revised forecast[13] - The company expects a full-year ROE in the 10% range, with H1 ROE hitting 12.7%, up 3.9 percentage points from the end of FY25.3[13, 21] Capital Recycling & Investment - Capital gains for H1 FY26.3 reached 157.1 Billion JPY, with expectations of further gains in H2[27] - The company launched its first domestic PE fund with a total size of 2.5 Billion USD[6] - ORIX sold stakes in Greenko, Ormat, ORIX Asset Management and Loan Services Corp, and Nissay Leasing[6] Segment Performance - Segment profits increased by 42% YoY to 409.4 Billion JPY[35] - Environment and Energy segment profits increased sharply by 117.3 Billion JPY due to the Greenko exit, which included a 95 Billion JPY gain on sale/valuation gains[34] - Insurance segment saw higher investment income, contributing to overall profit growth[35] Shareholder Returns - The company increased the full-year dividend forecast to 153.67 JPY per share, a 16.3% increase[6, 14] - The company anticipates a full-year total payout ratio of 73%[15]

GenScript Biotech Corporation Overview - GenScript Biotech Corporation aims to be a leading global CDMO, known for cutting-edge technology, and a creator of solutions for a better life through bio-innovation[6] - The company's growth framework is built on innovation in DNA synthesis & design, protein design & engineering, and cell design & engineering[7] - The group's cash position is $966.6 million[11] - GenScript has a global presence, serving over 100 countries and regions with 200,000+ customers[14] Business Strategy and Financial Goals - By 2035, GenScript aims for $3 billion in revenue with over 20% operating margin, $3 billion accumulated licensing revenue, 50% revenue from products, and over 80% revenue from high-margin markets[20, 46] - The company is focusing on high-quality growth with better profitability[20] - GenScript is leveraging core technology advantages to accelerate products and high-value licensing, building a new growth engine with AI and digital engine[20] GenScript Life Science Group (LSG) - GenScript LSG has over 239,500 customers and 3,300+ employees, with 10% in R&D[59] - Accumulated citations of GenScript services & products in customer research publications exceed 112,200[65] - TurboCHOTM can produce antibodies from sequence in 5 days[98] ProBio (Biologics CRDMO) - ProBio aims to be a leading global CDMO, enabling customers to deliver life-changing therapies[6, 127] - The company has $371.1 million in cash position[137] - The biologics CDMO market is projected to be a $16 billion market with a 12% CAGR, while the CGT CDMO market is at $5.6 billion[166] - In vivo CAR-T trial starts grew 220% from 2024 to 2025[166] Bestzyme (Industrial Synthetic Biology) - Bestzyme's vision is to be the creator of solutions for a better life, powered by leading bio-innovation[6, 224] - The company has over 40% of staff in R&D, 60+ granted patents, and 130+ patent applications[233] - Bestzyme has a 23% revenue CAGR and 22% gross profit CAGR in 2022-2024[233]

Financial Performance - Fortive's revenue reached $4.1 billion, with a ~30% Adjusted EBITDA Margin[8] - The company generated $1.2 billion in Adjusted EBITDA[8] - Free cash flow amounted to $0.9 billion, exceeding 100% conversion on Adjusted Net Income[8] - Adjusted Gross Profit Margin stood at ~65%[8] - Core revenue growth from FY 2019 to FY 2024 was 4%, but only 2% in TTM Q3 2025[8, 9] Segment Performance - Intelligent Operating Solutions (IOS) reported $2.8 billion in revenue with a 35% Adjusted EBITDA Margin[8] - Advanced Healthcare Solutions (AHS) achieved $1.3 billion in revenue with a 27% Adjusted EBITDA Margin[8] Capital Allocation - Fortive deployed $1 billion in Q3 for share repurchases, representing approximately 21 million shares or 6% of fully diluted shares outstanding[12] Strategic Initiatives - The company completed the separation of its former Precision Technologies segment on June 28, 2025[4] - Fortive is focused on faster profitable organic growth powered by the Fortive Business System (FBS)[11]

Baird Global Industrial Conference Lucian Boldea, President and CEO Mike Discenza, Vice President and CFO The Company cautions that actual results may differ materially from those projected or implied in forward-looking statements due to a variety of important factors, including: fluctuations in customer demand for the Company's products or services; unanticipated changes in business relationships with customers or their purchases from the Company; changes in the financial health of the Company's customers, ...

Business Updates - Oklo was selected for three DOE Reactor Pilot Program projects, potentially accelerating deployment timelines[17, 20, 21] - Groundbreaking for the Aurora-INL powerhouse was completed in September, with site earthworks beginning in October[18, 26, 27] - Atomic Alchemy targets first operations by July 2026, focusing on isotope production[18, 31] - The company announced a Fuel Recycling Facility as phase I of an advanced fuel center in Tennessee, with a potential investment of up to $168 billion[19, 41, 44] - Oklo signed a Joint Technology Development Agreement with Blykalla and a fuel fabrication and manufacturing partnership with newcleo to collaborate on advanced nuclear ecosystem[17, 48, 50] Financial Highlights - The company's 3Q 2025 loss from operations was $363 million, driven by payroll, general business expenses, and non-cash stock-based compensation[52, 54] - The 3Q 2025 loss before income taxes was $292 million, derived from the loss from operations adjusted for net interest and dividend income of approximately $71 million[52] - Year-to-date 2025 cash used in operating activities totaled $487 million, including a net loss of $642 million, adjusted primarily for non-cash charges[53] - As of September 30, 2025, Oklo had cash and marketable securities totaling $1184 billion, including $4100 million in cash and equivalents and $7735 million in marketable securities[19, 54, 55]